AJR Women's Imaging Online
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Forman, H. P.
Right arrow Articles by McClennan, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Forman, H. P.
Right arrow Articles by McClennan, B. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

American Journal of Roentgenology, Vol 162, 1125-1128, Copyright © 1994 by American Roentgen Ray Society


ARTICLES

CT screening for comorbid disease in patients with prostatic carcinoma: is it cost-effective?

HP Forman, JP Heiken, JA Brink, HS Glazer, LA Fox and BL McClennan
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110.

OBJECTIVE. The role of imaging in patients with newly diagnosed prostatic carcinoma is controversial. Currently, 35% of patients with prostatic carcinoma undergo CT at the time of diagnosis, despite reports of the lack of efficacy of CT in staging the disease. We sought to evaluate the cost-effectiveness of CT in detecting unrelated comorbid disease (significant disease unrelated to prostatic carcinoma) that might affect decisions on treatment in this population of patients. MATERIALS AND METHODS. We reviewed the medical records of 273 consecutive patients with newly diagnosed prostatic carcinoma who had CT of the abdomen and pelvis as part of their preoperative evaluation. Using costs based on Medicare reimbursements, we assessed the impact of the CT findings (related to comorbid disease) on overall costs and savings related to the workup and treatment of these patients. RESULTS. Sixty-six patients (24%) had findings suggestive of comorbid disease. The CT findings had near-term impact on only four patients (two in whom large abdominal aortic aneurysms were detected and two in whom second primary cancers were found), despite nearly $155,000 spent on the screening CT scans and more than $4400 spent on further evaluation of false-positive CT findings. The clinical impact varied from intervening semiurgent surgery to cancellation of prostatic surgery and institution of radiation therapy. CONCLUSION. CT is not cost-effective in screening for comorbid disease that would affect treatment in patients with newly diagnosed prostatic carcinoma.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
M. C. Smitt and V. K. Mehta
Is Diagnostic Review of Radiotherapy-Planning CT Scans Important in the Conformal Therapy Era?
Am. J. Roentgenol., September 1, 2001; 177(3): 521 - 524.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
A. K. Hara, C. D. Johnson, R. L. MacCarty, and T. J. Welch
Incidental Extracolonic Findings at CT Colonography
Radiology, May 1, 2000; 215(2): 353 - 357.
[Abstract] [Full Text]


Home page
RadiologyHome page
J. S. Miller, M. L. Puckett, and P. A. S. Johnstone
Frequency of Coexistent Disease at CT in Patients with Prostate Carcinoma Selected for Definitive Radiation Therapy: Is Limited Treatment-planning CT Adequate?
Radiology, April 1, 2000; 215(1): 41 - 44.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Roentgen Ray Society.